Navigation Links
CryoLife, Inc. Receives Tissue From 100,000th Donor, Marking Industry Milestone
Date:1/21/2009

ATLANTA, Jan. 21 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), announced today that it achieved an industry milestone when it received tissue from its 100,000th individual donor. The tissue, received January 14, 2009 came from a Kansas-based organ and tissue procurement organization.

Since 1984, through the generosity of donor families and with the support of the organ and tissue procurement organizations, CryoLife has been able to provide more than 160,000 cryopreserved tissues for transplant.

More than 40 percent of the cardiac tissue preserved by CryoLife is implanted into children for whom the availability of cryopreserved allograft tissue can provide the best chance for a normal, active lifestyle. In addition, cryopreserved allograft vascular tissues have enabled patients with impaired circulatory systems to avoid lower limb amputations.

"It has been very gratifying to be able to provide life-saving and life-enhancing tissues to so many patients over the years," said Steven G. Anderson, president and CEO of CryoLife, "However, none of our work would be possible without the generosity of donors and their families who give so selflessly at a time of personal tragedy. We are grateful to the many people who register as organ and tissue donors. Their kindness is awe-inspiring."

CryoLife encourages everyone to support their local organ or tissue procurement organizations and health care professionals in their efforts to provide increased awareness of organ and tissue donation options. For additional information about organ donation, contact your local organ or tissue procurement organization or the American Association of Tissue Banks at www.aatb.org.

About CryoLife

Founded in 1984, CryoLife, Inc. is a leader in the processing and distribution of implantable living human tissues for use in cardiac and vascular surgeries throughout the U.S. and Canada. The Company has received FDA clearance for the CryoValve(R) SG pulmonary human heart valve, processed using CryoLife's proprietary SynerGraft(R) Technology. The Company's BioGlue(R) Surgical Adhesive is FDA approved as an adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels. BioGlue is also CE marked in the European Community and approved in Canada and Australia for use in soft tissue repair. CryoLife distributes Hemostase MPH, a hemostatic agent, in much of the U.S. for use in cardiac and vascular surgery and in the United Kingdom, Germany, France, and Canada for cardiac, vascular, and general surgery, subject to certain exclusions. The Company also distributes the CryoLife-O'Brien(R) Stentless Porcine Aortic Bioprosthesis, which is CE marked for distribution within the European Community.

For additional information about the Company, visit CryoLife's Web Site: http://www.cryolife.com.

    Media Contacts:
    D. Ashley Lee                                         Katie Brazel
    Executive Vice President, Chief Financial             Fleishman Hillard
    Officer and Chief Operating Officer                   Phone: 404-739-0150
    Phone: 770-419-3355


'/>"/>
SOURCE CryoLife, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
5. IsoTis Receives FDA Clearance for Accell Family of Products
6. Actavis Receives Approval of Fentanyl Transdermal System in the U.S.
7. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
8. IDM Pharma Receives Not Approvable Letter for Mifamurtide (L-MTP-PE) for the Treatment of Osteosarcoma
9. XTL Receives Staff Letter From NASDAQ
10. XTL Receives Staff Letter From NASDAQ; XTL may Transfer its ADR Listing to the NASDAQ Capital Market
11. Hemo-Stream(TM) Chronic Dialysis Catheter Receives FDA Clearance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... Florida , March 22, 2017 ... ... various cancer conditions are being pressured as of late due ... for cancer pain management has a dramatic impact on patient,s ... research and development activities for identifying new forms of opioid ...
(Date:3/22/2017)... 22, 2017   VWR (NASDAQ: ... product and service solutions to laboratory and ... acquired EPL Archives, Inc., an international biorepository ... entire regulated product research, development and commercialization ... and ancillary services. EPL Archives is widely ...
(Date:3/22/2017)... Linda, Ca (PRWEB) , ... March 21, 2017 ... ... and clearance of biologics. To acquire information on the desired increase and/or decrease ... the biopharmaceutical industry for rapid N-glycosylation profiling of therapeutic antibodies. , To ...
(Date:3/22/2017)... ... March 21, 2017 , ... The Conference Forum has announced ... to be held on May 10-11, 2017, at the Colonnade Hotel in Boston, MA. ... Chief Medical Officer peer-to-peer learning, benchmarking and support. , “The Chief Medical Officer faces ...
Breaking Biology Technology:
(Date:2/21/2017)... 2017 Der weltweite Biobanking-Sektor wird ... einem Gespräch mit mehr als 50 Vertretern aus verschiedenen Branchen ... gilt, um diese Prognose zu realisieren. ... Zu den ... finanziellen Mittel für die Biobank, die Implementierung Zeit sparender ...
(Date:2/14/2017)... -- Wake Forest Baptist Medical Center today announced Julie Ann Freischlag, ... (CEO). Freischlag joins the medical center on May 1 ... who last year announced that he would transition to ... it since 2008.   As CEO, Freischlag ... academic health system, which includes Wake Forest School of ...
(Date:2/13/2017)... , Feb. 13, 2017 Former 9/11 Commission ... Judiciary Committee, Janice Kephart of Identity Strategy ... Donald Trump,s "Executive Order: Protecting the Nation ... 27, 2017):  "As President Trump,s ,Travel Ban, ... has now essentially banned the travel ban, it is ...
Breaking Biology News(10 mins):